Status:
COMPLETED
Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration
Lead Sponsor:
University Hospital, Caen
Collaborating Sponsors:
Genzyme, a Sanofi Company
Ligue contre le cancer, France
Conditions:
C10.114.375.500
Eligibility:
All Genders
Brief Summary
The study design matches with a multicenter observational ambispective study. A first pilot study will be undertaken in Caen center and is expected to be extended to Rouen and Lille center. So patient...
Detailed Description
Multiple sclerosis is known to be the first non traumatic cause of disability in young people. Multiple sclerosis is described as a chronic inflammatory immune-mediated disease of the central nervous ...
Eligibility Criteria
Inclusion
- Patients registered in EDMUS database.
- Patients with an initial and definite diagnosis of Relapsing-Remitting Multiple Sclerosis.
- An established diagnosis from January 1st 1995 to the end of the study.
Exclusion
- Patients not registered in EDMUS database.
- Patient with a diagnosis of Primary Progressive Multiple Sclerosis
- Patients with a diagnosis established before January 1st 1995
Key Trial Info
Start Date :
November 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT03308994
Start Date
November 1 2017
End Date
December 31 2019
Last Update
October 22 2020
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Groupement des Hôpitaux de l'Institut Catholique de Lille (HICL)
Lille, Hauts-de-France, France, 59020
2
University Hospital of Lille
Lille, Hauts-de-France, France, 59037
3
University Hospital Center of Caen
Caen, Normandy, France, 14033
4
University Hospital of Rouen
Rouen, Normandy, France, 76031